دورية أكاديمية
أعرض في EDS

Results of patch testing in acute generalized exanthematous pustulosis (AGEP): A literature review.

التفاصيل البيبلوغرافية
العنوان: Results of patch testing in acute generalized exanthematous pustulosis (AGEP): A literature review.
المؤلفون: de Groot AC; Dermatologist np, Wapserveen, The Netherlands.
المصدر: Contact dermatitis [Contact Dermatitis] 2022 Aug; Vol. 87 (2), pp. 119-141. Date of Electronic Publication: 2022 Mar 14.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Wiley Country of Publication: England NLM ID: 7604950 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0536 (Electronic) Linking ISSN: 01051873 NLM ISO Abbreviation: Contact Dermatitis Subsets: MEDLINE
أسماء مطبوعة: Publication: <2005-> : Oxford : Wiley
Original Publication: Copenhagen, Munksgaard.
مواضيع طبية MeSH: Acute Generalized Exanthematous Pustulosis*/diagnosis , Acute Generalized Exanthematous Pustulosis*/drug therapy , Acute Generalized Exanthematous Pustulosis*/etiology , Dermatitis, Allergic Contact*/complications, Amoxicillin/adverse effects ; Anti-Bacterial Agents/adverse effects ; Humans ; Patch Tests ; Pristinamycin/adverse effects
مستخلص: The literature on positive patch-test results in acute generalized exanthematous pustulosis (AGEP) is reviewed. Ninety-three drugs were identified that have together caused 259 positive patch tests in 248 patients with AGEP. The drug classes causing the highest number of reactions are beta-lactam antibiotics (25.9%), other antibiotics (20.8%), iodinated contrast media (7.3%), and corticosteroids (5.4%), together accounting for nearly 60% of all reactions. The highest number of reactions to individual drugs was to amoxicillin (n = 36), followed by pristinamycin (n = 25), diltiazem (n = 14), amoxicillin-clavulanic acid (n = 13), clindamycin (n = 11), and iomeprol (n = 8); 59 of the 93 drugs each caused a single case only. The "Top-10" drugs together caused over 50% of all reactions. The sensitivity of patch testing (percentage of positive reactions) in patients with AGEP is largely unknown, but may generally be ~50%, which also applies to pristinamycin. Patch testing in AGEP appears to be safe, although mild recurrence of AGEP skin symptoms or other rashes may occur occasionally. Clinical aspects of AGEP, including epidemiology, etiology and pathophysiology, clinical features, histology, treatment, and prognosis are briefly presented, as are diagnosing the disease and identifying the culprit drugs with patch tests, intradermal tests, in vitro tests, and challenge tests.
(© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
References: De Groot AC. Results of patch testing in drug reaction with eosinophilia and systemic symptoms (DRESS): a literature review. Contact Dermatitis. 2022; in press.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73(5):843-848.
Prange B, Marini A, Kalke A, Hodzic-Avdagic N, Ruzicka T, Hengge UR. Akute lokalisierte exanthematische Pustulose (ALEP) [acute localized exanthematous pustulosis (ALEP)]. J Dtsch Dermatol Ges. 2005;3(3):210-212. (Article in German).
Feldmeyer L, Heidemeyer K, Yawalkar N. Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy. Int J Mol Sci. 2016;17(8):1214.
De Groot AC. Monographs in Contact Allergy, Volume 4. Systemic Drugs. Boca Raton, FL: CRC Press Taylor and Francis Group; 2022:1031.
Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol. 1968;80(12):771-793.
Beylot C, Bioulac P, Doutre MS. Pustuloses exanthématiques aiguës généralisées, à propos de 4 cas. Ann Dermatol Venereol. 1980;107(1-2):37-48. (Article in French).
Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973-992.
Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996-2011.
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. 2017;1(1):96-108.
Paulmann M, Mockenhaupt M. Severe drug hypersensitivity reactions: clinical pattern, diagnosis, etiology and therapeutic options. Curr Pharm Des. 2016;22(45):6852-6861.
Paulmann M, Mockenhaupt M. Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. J Dtsch Dermatol Ges. 2015;13(7):625-645.
Sidoroff A. Acute generalized exanthematous pustulosis. Hautarzt. 2014;65(5):430-435. (Article in German).
Dodiuk-Gad RP, Laws PM, Shear NH. Epidemiology of severe drug hypersensitivity. Semin Cutan Med Surg. 2014;33(1):2-9.
Sidoroff A. Acute generalized exanthematous pustulosis. In: French LE, ed. Adverse Cutaneous Drug Eruptions. Chem Immunol Allergy. Vol 97. Basel: Karger; 2012:139-148.
Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am. 2010;94(4):727-742.
Speeckaert MM, Speeckaert R, Lambert J, Brochez L. Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts. Eur J Dermatol. 2010;20(4):425-433.
Halevy S. Acute generalized exanthematous pustulosis. Curr Opin Allergy Clin Immunol. 2009;9(4):322-328.
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP) - results of a multinational case-control study (EuroSCAR). Br J Dermatol. 2007;157(5):989-996.
Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug hypersensitivity reactions. Curr Opin Allergy Clin Immunol. 2019;19(4):283-293.
Hotz C, Valeyrie-Allanore L, Haddad C, et al. Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. Br J Dermatol. 2013;169(6):1223-1232.
Halevy S, Kardaun SH, Davidovici B, Wechsler J. EuroSCAR and RegiSCAR study group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases. Br J Dermatol. 2010;163(6):1245-1252.
Kardaun SH, Kuiper H, Fidler V, Jonkman MF. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol. 2010;37(12):1220-1229.
Sidoroff A, Halevy S, Bavinck JN, Vaillant L, Roujeau JC. Acute generalized exanthematous pustulosis (AGEP) - a clinical reaction pattern. J Cutan Pathol. 2001;28(3):113-119.
Barbaud A. Skin testing and patch testing in non-IgE-mediated drug allergy. Curr Allergy Asthma Rep. 2014;14(6):442.
Wolkenstein P, Chosidow O, Fléchet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4):234-236.
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol. 2013;168(3):555-562.
De Groot AC. Patch testing in drug eruptions: practical aspects and literature review of eruptions and culprit drugs. Dermatitis. 2022;36(1):16-30.
Lehloenya RJ, Peter JG, Copascu A, Trubiano JA, Phillips EJ. Delabeling delayed drug hypersensitivity: how far can you safely go? J Allergy Clin Immunol Pract. 2020;8(9):2878-2895.e6.
Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev. 2013;34(1):15-38.
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol. 2019;143(1):66-73.
Bergmann MM, Caubet JC. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. Curr Pharm Des. 2019;25(36):3872-3880.
Trubiano JA, Douglas AP, Goh M, Slavin MA, Phillips EJ. The safety of antibiotic skin testing in severe T-cell-mediated hypersensitivity of immunocompetent and immunocompromised hosts. J Allergy Clin Immunol Pract. 2019;7(4):1341-1343.e1.
Barbaud A, Weinborn M, Garvey L, et al. Intradermal tests with drugs: an approach to standardization. Front Med (Lausanne). 2020;7:156.
Brockow K, Garvey LH, Aberer W, et al. ENDA/EAACI drug allergy interest group. Skin test concentrations for systemically administered drugs -- an ENDA/EAACI drug allergy interest group position paper. Allergy. 2013;68(6):702-712.
Soria A, Amsler E, Bernier C, et al. DRESS and AGEP reactions to iodinated contrast media: a French case series. J Allergy Clin Immunol Pract. 2021;9(8):3041-3050.
Demoly P, Adkinson NF, Brockow K, et al. International consensus on drug allergy. Allergy. 2014;69(4):420-437.
Mayorga C, Celik G, Rouzaire P, et al. In vitro tests for drug hypersensitivity reactions: an ENDA/EAACI drug allergy interest group position paper. Allergy. 2016;71(8):1103-1134.
Aberer W, Bircher A, Romano A, et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003;58(9):854-863.
Villani A, Baldo A, De Fata SG, Desiato V, Ayala F, Donadio C. Acute localized exanthematous pustulosis (ALEP): review of literature with report of case caused by amoxicillin-clavulanic acid. Dermatol Ther (Heidelb). 2017;7(4):563-570.
Safa I, Ines L, Noureddine L, et al. Acute localized exanthematous pustulosis: clinical features, pathophysiology, and therapy. Dermatol Ther. 2021;34(5):e15087.
Tsutsumi R. Acute localized exanthematous pustulosis caused by a herbal medicine, dai-kenchu-to. Contact Dermatitis. 2018;79(4):257-259.
Lahouel M, Mokni S, Denguezli M. Acute localized exanthematous pustulosis induced by a spider bite. Am J Trop Med Hyg. 2020;103(3):937-938.
Ryder ENC, Perkins W. Acute localised exanthematous pustulosis: case report, review of the literature and proposed diagnostic criteria. Australas J Dermatol. 2018;59(3):226-227.
Tresch S, Cozzio A, Kamarashev J, et al. T cell-mediated acute localized exanthematous pustulosis caused by finasteride. J Allergy Clin Immunol. 2012;129(2):589-594.
Gómez Torrijos E, Cortina de la Calle MP, Méndez Díaz Y, et al. Acute localized exanthematous pustulosis due to bemiparin. J Investig Allergol Clin Immunol. 2017;27(5):328-329.
Navarro Triviño FJ, Linares-González L, Ródenas-Herranz T, Llamas-Molina JM, Ruiz-Villaverde R. Acute localized exanthematous pustulosis (ALEP) induced by iomeprol (Iomeron 350): a diagnostic challenge. Contact Dermatitis. 2021;85(1):95-97.
Kostaki M, Polydorou D, Adamou E, Chasapi V, Antoniou C, Stratigos A. Acute localized exanthematous pustulosis due to metronidazole. J Eur Acad Dermatol Venereol. 2019;33(3):e109-e111.
Treudler R, Grunewald S, Gebhardt C, Simon J-C. Prolonged course of acute generalized exanthematous pustulosis with liver involvement due to sensitization to amoxicillin and paracetamol. Acta Derm Venereol. 2009;89(3):314-315.
Léger F, Machet L, Jan V, Machet C, Lorette G, Vaillant L. Acute generalized exanthematous pustulosis associated with paracetamol. Acta Derm Venereol. 1998;78(3):222-223.
Chen Y-C, Fang L-C, Wang J-Y. Paracetamol-induced acute generalized exanthematous pustulosis in a 4-year-old girl. Dermatologica Sinica. 2016;34(1):49-51.
Mashiah J, Brenner S. A systemic reaction to patch testing for the evaluation of acute generalized exanthematous pustulosis. Arch Dermatol. 2003;139(9):1181-1183.
Jachiet M, Bellon N, Assier H, et al. Cutaneous adverse drug reaction to oral acetazolamide and skin tests. Dermatology. 2013;226(4):347-352.
Serra D, Ramos L, Brinca A, Gonçalo M. Acute generalized exanthematous pustulosis associated with acyclovir, confirmed by patch testing. Dermatitis. 2012;23(2):99-100.
Kubin ME, Jackson P, Riekki R. Acute generalized exanthematous pustulosis secondary to acyclovir confirmed by positive patch testing. Acta Derm Venereol. 2016;96(6):860-861.
Bérot V, Gener G, Ingen-Housz-Oro S, et al. Cross-reactivity in beta-lactams after a nonimmediate cutaneous adverse reaction: experience of a reference Centre for toxic bullous diseases and severe cutaneous adverse reactions. J Eur Acad Dermatol Venereol. 2020;34(4):787-794.
Assier H, Valeyrie-Allanore L, Gener G, Verlinde Carvalh M, Chosidow O, Wolkenstein P. Patch testing in non-immediate cutaneous adverse drug reactions: value of extemporaneous patch tests. Contact Dermatitis. 2017;77(5):297-302.
Watanabe A, Yoneda M, Shoda Y. A twin case of acute juvenile generalized pustular psoriasis accompanied by generalized exanthematous pustulosis (AGEP). Skin Res. 2012;11(3):209-214. (Article in Japanese).
Jörg L, Yerly D, Helbling A, Pichler W. The role of drug, dose and the tolerance/intolerance of new drugs in multiple drug hypersensitivity syndrome (MDH). Allergy. 2020;75(5):1178-1187.
Watts TJ, Thursfield D, Haque R. Patch testing for the investigation of nonimmediate cutaneous adverse drug reactions: a prospective single center study. J Allergy Clin Immunol Pract. 2019;7(8):2941-2943.e3.
Tajmir-Riahi A, Wörl P, Harrer T, Schliep S, Schuler G, Simon M. Life-threatening atypical case of acute generalized exanthematous pustulosis. Int Arch Allergy Immunol. 2017;174(2):108-111.
McDonald KA, Pierscianowski TA. A case of amoxicillin-induced acute generalized exanthematous pustulosis presenting as septic shock. J Cutan Med Surg. 2017;21(4):351-355.
Gensch K, Hodzic-Avdagic N, Megahed M, Ruzicka T, Kuhn A. Acute generalized exanthematous pustulosis with confirmed type IV allergy. Report of 3 cases. Hautarzt. 2007;58(3):250-252, 254-255. (Article in German).
Pinho A, Marta A, Coutinho I, Gonçalo M. Long-term reproducibility of positive patch test reactions in patients with non-immediate cutaneous adverse drug reactions to antibiotics. Contact Dermatitis. 2017;76(4):204-209.
Britschgi M, Steiner UC, Schmid S, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest. 2001;107(11):1433-1441.
Whittam LR, Wakelin SH, Barker JN. Generalized pustular psoriasis or drug-induced toxic pustuloderma? The use of patch testing. Clin Exp Dermatol. 2000;25(2):122-124.
Ponvert C, Le Bourgeois M, Karila C, De Blic J, Scheinmann P. Allergy to betalactam antibiotics in child: diagnosis of non immediate hypersensitivity by means of intradermal and patch-tests and challenge. Rev Franc Allergol Immunol Clin. 2004;44(4):379-381.
Syrigou E, Grapsa D, Charpidou A, Syrigos K. Acute generalized exanthematous pustulosis induced by amoxicillin/clavulanic acid: report of a case presenting with generalized lymphadenopathy. J Cutan Med Surg. 2015;19(6):592-594.
Bomarrito L, Zisa G, Delrosso G, Farinelli P, Galimberti M. A case of acute generalized exanthematous pustulosis due to amoxicillin-clavulanate with multiple positivity to beta-lactam patch testing. Eur Ann Allergy Clin Immunol. 2013;45(5):178-180.
Henning MA, Opstrup MS, Taudorf EH. Acute generalized exanthematous pustulosis to amoxicillin. Dermatitis. 2019;30(4):274-275.
Hernández-Aragüés I, MS DSMG, Pérez-Esquerra PR, Simal-Gómez G. Cutaneous drug reactions: acute rash with pinhead-sized pustules. Eur J Dermatol. 2018;28(6):859-860.
Li PH, Wong JCY, Lau CS. Importance of allergological evaluation and skin testing for severe cutaneous adverse reactions: a case report. Hong Kong Med J. 2020;26(5):444-445.
Buffiere I. Acute generalized exanthematic pustulosis (AGEP).One case report [Pustulose exanthematique aigue generalisee. A propos d'un cas]. Nouvelles Dermatologiques. 1998;17(3):124-125. (Article in French).
De Thier F, Blondeel A, Song M. Acute generalized exanthematous pustulosis induced by amoxycillin with clavulanate. Contact Dermatitis. 2001;44(2):114-115.
Büyük Yaytokgil Ş, Güvenir H, Külhaş Celík İ, et al. Evaluation of drug patch tests in children. Allergy Asthma Proc. 2021;42(2):167-174.
Harries MJ, McIntyre SJ, Kingston TP. Co-amoxiclav-induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis. 2006;55(6):372.
Amaral L, Carneiro-Leão L, Cernadas JR. Acute generalized exanthematous pustulosis due to clavulanic acid. J Allergy Clin Immunol Pract. 2020;8(3):1083-1084.
Matsumoto Y, Okubo Y, Yamamoto T, Ito T, Tsuboi R. Case of acute generalized exanthematous pustulosis caused by ampicillin/cloxacillin sodium in a pregnant woman. J Dermatol. 2008;35(6):362-364.
Özmen S, Misirlioglu ED, Gurkan A, Arda N, Bostanci I. Is acute generalized exanthematous pustulosis an uncommon condition in childhood? Allergy. 2010;65(11):1490-1492.
Ueda T, Abe M, Okiyama R, et al. Acute generalized exanthematous pustulosis due to allylisopropylacetylurea: role of IL-17-producing T cells. Eur J Dermatol. 2011;21(1):140-141.
Isogai Z, Sunohara A, Tsuji T. Pustular drug eruption due to bacampicilin hydrochloride in a patient with psoriasis. J Dermatol. 1998;25(9):612-615.
Harber ID, Adams KV, Casamiquela K, Helms S, Benson BT, Herrin V. Bendamustine-induced acute generalized exanthematous pustulosis confirmed by patch testing. Dermatitis. 2017;28(4):292-293.
Alava-Cruz C, Rojas Pérez-Ezquerra P, Pelta-Fernández R, Zubeldia-Ortuño JM, de Barrio-Fernández M. Acute generalized exanthematous pustulosis due to benznidazole. J Allergy Clin Immunol Pract. 2014;2(6):800-802.
Gambini D, Sena P, Raponi F, et al. Systemic allergic dermatitis presenting as acute generalized exanthematous pustulosis due to betamethasone sodium phosphate. Contact Dermatitis. 2020;82(4):250-252.
Altaykan A, Boztepe G, Erkin G, Ozkaya O, Ozden E. Acute generalized exanthematous pustulosis induced by bleomycin and confirmed by patch testing. J Dermatolog Treat. 2004;15(4):231-234.
Caldas R, Campos-Lopes S, Guimarães MJ, Areal J, Alves M, Pereira T. Patch test-proven delayed-type hypersensitivity from naltrexone/bupropion possibly eliciting psoriasis. Contact Dermatitis. 2021;85(4):456-458.
Duran-Ferreras E, Mir-Mercader J, Morales-Martinez MD, Martinez-Parra C. Anticonvulsant hypersensitivity syndrome with severe repercussions in the skin and kidneys. Rev Neurol. 2004;38(12):1136-1138. (Article in Spanish).
Haskova M. Acute generalized exanthematous pustulosis (AGEP): confirmation by in vivo patch and prick tests. Cesko-Slovenska Dermatol. 1999;74(6):260-261. (Article in Czech).
Grange-Prunier A, Roth B, Kleinclaus I, Fagot JP, Guillaume JC. Acute generalized exanthematous pustulosis induced by carbimazole (Neomercazole): first reported case and value of patch tests. Ann Dermatol Venereol. 2006;133(8-9Pt.1):708-710. (Article in French).
Namoju R, Ismail M, Kumar Golla V, Bamini T, Lakshmi Akarapu T, Baloju D. A case of acute generalized exanthematous pustulosis by cefixime with oral mucosal involvement. Curr Drug Saf. 2020;15(3):236-239.
Chaabane A, Aouam K, Gassab L, Njim L, Boughattas NA. Acute generalized exanthematous pustulosis (AGEP) induced by cefotaxime. Fundam Clin Pharmacol. 2010;24(4):429-432.
Chaabane A, Aouam K, Harrathi K, et al. Acute generalised exanthematous pustulosis (AGEP) after cefotaxime use. BMJ Case Rep. 2009;2009:bcr06.2008.0343.
Salman A, Yucelten D, Akin Cakici O, Kepenekli KE. Acute generalized exanthematous pustulosis due to ceftriaxone: report of a pediatric case with recurrence after positive patch test. Pediatr Dermatol. 2019;36(4):514-516.
Nacaroglu HT, Celegen M, Ozek G, et al. Acute generalized exanthematous pustulosis induced by ceftriaxone use. Postepy Dermatol Alergol. 2014;31(4):269-271.
Stingeni L, Francisci D, Bianchi L, et al. Severe adverse drug reaction in SARS-CoV-2 infection: AGEP induced by ceftriaxone and confirmed by patch test. Contact Dermatitis. 2021;85(3):366-368.
Shin HT, Park SW, Lee KT, et al. A case of celecoxib induced acute generalized exanthematous pustulosis. Ann Dermatol. 2011;23(Suppl.3):S380-S382.
Yang CC, Lee JY, Chen WC. Acute generalized exanthematous pustulosis caused by celecoxib. J Formos Med Assoc. 2004;103(7):555-557.
Marques S, Milpied B, Foulc P, Barbarot S, Cassagnau E, Stalder JF. Severe cutaneous drug reactions to celecoxib (Celebrex). Ann Dermatol Venereol. 2003;130(11):1051-1055.
Khan M, Wakelin S. Cetirizine induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis. 2020;82(4):238-239.
Lee AY, Yoo SH. Chloramphenicol induced acute generalized exanthematous pustulosis proved by patch test and systemic provocation. Acta Derm Venereol. 1999;79(5):412-413.
Häusermann P, Scherer K, Weber M, Bircher AJ. Ciprofloxacin-induced acute generalized exanthematous pustulosis mimicking bullous drug eruption confirmed by a positive patch test. Dermatology. 2005;211(3):277-280.
Serra D, Gonçalo M, Mariano A, Figueiredo A. Pustular psoriasis and drug-induced pustulosis. G Ital Dermatol Venereol. 2011;146(2):155-158. (Article in Italian).
Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones. Clin Exp Allergy. 2006;36(1):59-69.
Pinho A, Coutinho I, Gameiro A, Gouveia M, Gonçalo M. Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. J Eur Acad Dermatol Venereol. 2017;31(2):280-287.
Smeets TJ, Jessurun N, Härmark L, Kardaun SH. Clindamycin-induced acute generalised exanthematous pustulosis: five cases and a review of the literature. Neth J Med. 2016;74(10):421-428.
Gilissen L, Huygens S, Goossens A, Breynaert C, Schrijvers R. Utility of patch testing for the diagnosis of delayed-type drug hypersensitivity reactions to clindamycin. Contact Dermatitis. 2020;83(3):237-239.
Valois M, Phillips EJ, Shear NH, Knowles SR. Clindamycin-associated acute generalized exanthematous pustulosis. Contact Dermatitis. 2003;48(3):169.
El Khoury M, Assier H, Gener G, et al. Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. Br J Dermatol. 2018;179(4):978-979.
Llamas-Velasco M, Godoy A, Sánchez-Pérez J, García-Diez A, Fraga J. Acute generalized exanthematous pustulosis with histopathologic findings of lymphomatoid drug reaction. Am J Dermatopathol. 2013;35(6):690-691.
Yamamoto A, Goto N, Kanki H, Horikawa T, Nishigori C. A case of acute generalized exanthematous pustulosis (AGEP) with acute kidney injury. Skin Res. 2009;8(5):546-550. (Article in Japanese).
Barbaud A, Reichert-Penetrat S, Tréchot P, et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998;139(1):49-58.
Demitsu T, Kosuge A, Yamada T, Usui K, Katayama H, Yaoita H. Acute generalized exanthematous pustulosis induced by dexamethasone injection. Dermatology. 1996;193(1):56-58.
Machet L, Martin L, Machet MC, Lorette G, Vaillant L. Acute generalized exanthematous pustulosis induced by dextropropoxyphene and confirmed by patch testing. Acta Derm Venereol. 2000;80(3):224-225.
Assier H, Ingen-Housz-Oro S, Zehou O, Hirsch G, Chosidow O, Wolkenstein P. Strong reactions to diltiazem patch tests: plea for a low concentration. Contact Dermatitis. 2020;83(3):224-225.
de Santa S, María García M, Noguerado-Mellado B, Perez-Ezquerra PR, Hernandez-Aragües I, De Barrio FM. Acute generalized exanthematous pustulosis due to diltiazem: investigation of cross-reactivity with other calcium channel blockers. J Allergy Clin Immunol Pract. 2016;4(3):765-766.
Girardi M, Duncan KO, Tigelaar RE, Imaeda S, Watsky KL, McNiff JM. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. Am J Dermatopathol. 2005;27(4):343-346.
Jan V, Machet L, Gironet N, et al. Acute generalized exanthematous pustulosis induced by diltiazem: value of patch testing. Dermatology. 1998;197(3):274-275.
Vicente-Calleja JM, Aguirre A, Landa N, Crespo V, González-Pérez R, Diaz-Pérez JL. Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing. Br J Dermatol. 1997;137(5):837-839.
Wakelin SH, James MP. Diltiazem-induced acute generalised exanthematous pustulosis. Clin Exp Dermatol. 1995;20(4):341-344.
Serrão V, Caldas Lopes L, Campos Lopes JM, Lobo L, Ferreira A. Acute generalized exanthematous pustulosis associated with diltiazem. Acta Med Port. 2008;21(1):99-102. (Article in Portuguese).
Nishiimura T, Yoshioka K, Katoh J, et al. Pustular reaction induced by diltiazem HCl. Skin Res. 1991;33(Suppl.10):251-254. (Article in Japanese, data cited in ref. 46).
Wolkenstein P, Chosidow O, Fléchet ML, et al. Intéret des épicutanés dans !es toxicodermies graves. Ann Dermatol Venereol. 1995;C53: (bibliographical data incomplete, data cited in ref. 118).
Yamamoto Y, Kadota M, Nishimura Y. A case of eperisone hydrochloride-induced acute generalized exanthematous pustulosis. J Dermatol. 2004;31(9):769-770.
Faber M, Maucher OM, Stengel R, Goerttler E. Eprazinonexanthem mit subkornealer Pustelbildung [Eprazinone exanthema with subcorneal pustulosis]. Hautarzt. 1984;35(4):200-203. (Article in German).
Fernando SL. Ertapenem-induced acute generalized exanthematous pustulosis with cross-reactivity to other beta-lactam antibiotics on patch testing. Ann Allergy Asthma Immunol. 2013;111(2):139-140.
Moreau A, Dompmartin A, Castel B, Remond B, Leroy D. Drug-induced acute generalized exanthematous pustulosis with positive patch tests. Int J Dermatol. 1995;34(3):263-266.
Mäkelä L, Lammintausta K. Etoricoxib-induced acute generalized exanthematous pustulosis. Acta Derm Venereol. 2008;88(2):200-201.
Van Hattem S, Beerthuizen GI, Kardaun SH. Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. Br J Dermatol. 2014;171(6):1539-1545.
Di Lernia V, Ricci C. Fluconazole-induced acute generalized exanthematous pustulosis. Indian J Dermatol. 2015;60(2):212.
Chtioui M, Cousin-Testard F, Zimmermann U, Amar A, Saiag P, Mahé E. Fluindione-induced acute generalised exanthematous pustulosis confirmed by patch testing. Ann Dermatol Venereol. 2008;135(4):295-298. (Article in French).
Thurot C, Reymond JL, Bourrain JL, Pinel N, Béani JC. Pustulose exanthématique aiguë généralisée à la fluindione avec atteinte rénale. Ann Dermatol Venereol. 2003;130(12Pt.1):1146-1149. (Article in French).
Bordel Gómez MT, Martín García C, Meseguer Yebra C, Zafra Cobo MI, Cardeñoso Álvarez ME, Sánchez EJ. First case report of acute generalized exanthematous pustulosis (AGEP) caused by gadolinium confirmed by patch testing. Contact Dermatitis. 2018;78(2):166-168.
Charfi O, Kastalli S, Sahnoun R, Lakhoua G. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. Indian J Pharmacol. 2015;47(6):693-694.
Mofarrah R, Mofarrah R, Oshriehye M, Ghobadi Aski S, Nazemi N, Nooshiravanpoor P. The necessity of patch testing in determining the causative drug of AGEP. J Cosmet Dermatol. 2021;20(7):2156-2159.
Liccioli G, Mori F, Parronchi P, et al. Aetiopathogenesis of severe cutaneous adverse reactions (SCARs) in children: a 9-year experience in a tertiary care paediatric hospital setting. Clin Exp Allergy. 2020;50(1):61-73.
Chaabouni R, Bahloul E, Ennouri M, et al. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: a series of seven patients and review of the literature. Int J Dermatol. 2021;60(6):742-748.
O'Toole A, Lacroix J, Pratt M, Beecker J. Acute generalized exanthematous pustulosis associated with 2 common medications: hydroxyzine and benzocaine. J Am Acad Dermatol. 2014;71(4):e147-e149.
O'Toole AC, LaCroix J, Pratt M. Acute generalized exanthematous pustulosis (AGEP) caused: a case series and review of the guidelines for patch testing in cutaneous drug eruptions. Dermatitis. 2017;27(5):e4.
Lacroix J, Pratt MD. Acute generalized exanthematous pustulosis caused by Atarax® in a sensitized patient. Dermatitis. 2013;24(4):e2.
Tsai YS, Tu ME, Wu YH, Lin YC. Hydroxyzine-induced acute generalized exanthematous pustulosis. Br J Dermatol. 2007;157(6):1296-1297.
Utida T, Fujimura N, Ito K, Aihara M, Ikezawa Z. Hydroxyzine pamoate-induced acute generalized exanthematous pustulosis (AGEP) followed by Psoriasis vulgaris. Eur Ann allergy Clin Immunol. 2010;42(2):97 (Abstract).
Yasugi Y, Miyata A, Hirano A, et al. A case of acute generalized exanthematous pustulosis due to hydroxyzine pamoate. Skin Res. 2005;4(1):26-30. (Article in Japanese).
Belz D, Persa OD, Haese S, Hunzelmann N. Acute generalized exanthematous pustulosis caused by ibuprofen-diagnosis confirmed by patch testing. Contact Dermatitis. 2018;79(1):40-41.
Grandvuillemin A, Ripert C, Sgro C, Collet E. Iodinated contrast media-induced acute generalized exanthematous pustulosis confirmed by delayed skin tests. J Allergy Clin Immunol Pract. 2014;2(6):805-806.
Velter C, Schissler C, Moulinas C, et al. Acute generalized exanthematous pustulosis caused by an iodinated contrast radiocontrast medium for computed tomography arthrography of the knee. Contact Dermatitis. 2017;76(6):371-373.
Machet P, Marcé D, Ziyani Y, et al. Acute generalized exanthematous pustulosis induced by iomeprol with cross-reactivity to other iodinated contrast agents and mild reactions after rechallenge with iopromide and oral corticosteroid premedication. Contact Dermatitis. 2019;81(1):74-76.
Mizuta T, Kasami S, Shigehara Y, Kato M. Acute generalized exanthematous pustulosis caused by iopamidol with recurrence on rechallenge with iopromide. JAAD Case Rep. 2020;6(10):964-966.
Bavbek S, Sözener ZC, Aydin O, Ozdemir SK, Gül U, Heper AO. First case report of acute generalized exanthematous pustulosis due to intravenous iopromide. J Investig Allergol Clin Immunol. 2014;24(1):66-67.
Poliak N, Elias M, Cianferoni A, Treat J. Acute generalized exanthematous pustulosis: the first pediatric case caused by a contrast agent. Ann Allergy Asthma Immunol. 2010;105(3):242-243.
Katagiri K, Takayasu S. Drug induced acute generalized exanthematous pustulosis. J Dermatol. 1996;23(9):623-627.
Yamasaki R, Yamasaki M, Kawasaki Y, Nagasako R. Generalized pustular dermatosis caused by isoniazid. Br J Dermatol. 1985;112(4):504-506.
Gómez Torrijos E, García Rodríguez C, Sánchez Caminero MP, Castro Jiménez A, García Rodríguez R, Feo-Brito F. First case report of acute generalized exanthematous pustulosis due to labetalol. J Investig Allergol Clin Immunol. 2015;25(2):148-149.
Dewerdt S, Vaillant L, Machet L, de Muret A, Lorette G. Acute generalized exanthematous pustulosis induced by lansoprazole. Acta Derm Venereol. 1997;77(3):250.
Otsuka A, Tanizaki H, Okamoto N, Takagaki K. A case of acute generalized exanthematous pustulosis caused by lincomycin. J Dermatol. 2005;32(11):929-930.
Gonzalo-Garijo MA, Perez-Calderon R, De Argila D, Rodriguez-Nevado I. Metamizole-induced acute generalized exanthematous pustulosis. Contact Dermatitis. 2003;49(1):47-48.
Morant C, Devis T, Alcaraz I, Lefevre L, Caron J, Modiano P. Acute generalized exanthematous pustulosis due to meladinine with positive patch tests. Ann Dermatol Venereol. 2002;129(2):234-235. (Article in French).
Mussot-Chia C, Flechet ML, Napolitano M, Herson S, Frances C, Chosidow O. Methylprednisolone-induced acute generalized exanthematous pustulosis. Ann Dermatol Venereol. 2001;128(3Pt.1):241-243. (Article in French).
Watsky KL. Acute generalized exanthematous pustulosis induced by metronidazole: the role of patch testing. Arch Dermatol. 1999;135(12):93-94.
Watsky KL. Acute generalized exanthematous pustulosis due to metronidazole: the role of patch testing. Dermatitis. 1999;10(2):112 (Abstract).
Watsky KL. Acute generalized exanthematous pustulosis due to metronidazole: the role of patch testing. Dermatitis. 1998;9(1):67 (Abstract).
Sasaki K, Yamamoto T, Kishi M, Yokozeki H, Nishioka K. Acute exanthematous pustular drug eruption induced by mexiletine. Eur J Dermatol. 2001;11(5):469-471.
Tedbirt B, Viart-Commin MH, Carvalho P, Courville P, Tétart F. Severe acute generalized exanthematous pustulosis (AGEP) induced by miconazole oral gel with overlapping features of drug reaction with eosinophilia and systemic symptoms (DRESS). Contact Dermatitis. 2021;84(6):474-476.
Tetart F, Leger S, Carvalho P, Massy N. The interest of cooperation between clinician, allergologist and pharmacovigilance center: severe toxidermia complicated by myopericarditis induced by miconazole oral gel. Fund Clin Pharmacol. 2013;27(Suppl.1):61-62. (Abstract).
Yamamoto T, Minatohara K. Minocycline-induced acute generalized exanthematous pustulosis in a patient with generalized pustular psoriasis showing elevated level of sELAM-1. Acta Derm Venereol. 1997;77(2):168-169.
Kardaun SH, de Monchy JG. Acute generalized exanthematous pustulosis caused by morphine, confirmed by positive patch test and lymphocyte transformation test. J Am Acad Dermatol. 2006;55(2 Suppl):S21-S23.
Ghazawi FM, Colantonio S, Bradshaw S, Lacroix J, Pratt M. Acute generalized exanthematous pustulosis induced by topical morphine and confirmed by patch testing. Dermatitis. 2020;31(3):e22-e23.
Machet L, Jan V, Machet MC, Lorette G, Vaillant L. Acute generalized exanthematous pustulosis induced by nifuroxazide. Contact Dermatitis. 1997;36(6):308-309.
Spindler E, Janier M, Bonnin JM, Carlotti A, Daniel F. Pustulose exanthématique aigüe generalisée liée à la buphénine: un cas. Ann Dermatol Venereol. 1992;119(4):273-275. (Article in French, data cited in ref. 189).
Küchler A, Hamm H, Weidenthaler-Barth B, Kämpgen E, Bröcker EB. Acute generalized exanthematous pustulosis following oral nystatin therapy: a report of three cases. Br J Dermatol. 1997;137(5):808-811.
Ocerin-Guerra I, Gomez-Bringas C, Aspe-Unanue L, Ratón-Nieto JA. Nystatin-induced acute generalized exanthematous pustulosis. Actas Dermosifiliogr. 2012;103(10):927-928.
Poszepczynska-Guigne E, Viguier M, Assier H, Pinquier L, Hochedez P, Dubertret L. Acute generalized exanthematous pustulosis induced by drugs with low-digestive absorption: acarbose and nystatin. Ann Dermatol Venereol. 2003;130(4):439-442. (Article in French).
Couture-Lapointe C, Houle MC, Schreiber A. Acute generalized exanthematous pustulosis due to nystatin confirmed by scratch patch test. Contact Dermatitis. 2022;86(2):138-139.
Gammoudi R, Ben Salem C, Boussofara L, et al. Acute generalized exanthematous pustulosis induced by oxacillin confirmed by patch testing. Contact Dermatitis. 2018;79(2):108-110.
Buettiker U, Keller M, Picheler WJ, Braathen LR, Yamalkar N. Oral prednisolone induced acute generalized exanthematous pustulosis due to corticosteroids of group a confirmed by epicutaneous testing and lymphocyte transformation tests. Dermatology. 2006;213(1):40-43.
Ishii S, Hasegawa T, Hirasawa Y, Tsunemi Y, Kawashima M, Ikeda S. Acute generalized exanthematous pustulosis induced by oral prednisolone. J Dermatol. 2014;41(12):1135-1136.
Arianayagam S, Ieremia E, Arnold S. Acute generalised exanthematous pustulosis secondary to prednisolone: an unlikely suspect. Eur J Dermatol. 2021;31(1):119-121.
Ziemssen T, Bauer A, Bär M. Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP). Mult Scler. 2009;15(2):275-277.
Bär M, John L, Wonschik S, et al. Acute generalized exanthematous pustulosis induced by high-dose prednisolone in a young woman with optic neuritis owing to disseminated encephalomyelitis. Br J Dermatol. 2008;159(1):251-252.
Mayence C, Dompmartin A, Verneuil L, Michel M, Leroy D. Value of patch tests in pristinamycin-induced drug eruptions. Contact Dermatitis. 1999;40(3):161-162.
Landry Q, Zhang S, Ferrando L, Bourrain JL, Demoly P, Chiriac AM. Multiple drug hypersensitivity syndrome in a large database. J Allergy Clin Immunol Pract. 2019;8(1):258-266.e1.
Gebhardt M, Lustig A, Bocker T, Wollina U. Acute generalized exanthematous pustulosis (AGEP): manifestation of drug allergy to propicillin. Contact Dermatitis. 1995;33(3):204-205.
Moraga M, Vives R, Rodriguez J, et al. Disseminated acute pustulosis from pseudoephedrine. Allergy. 1995;50(suppl.26):215.
Mayo-Pampín E, Flórez A, Feal C, et al. Acute generalized exanthematous pustulosis due to pseudoephedrine with positive patch test. Acta Derm Venereol. 2006;86(6):542-543.
Padial MA, Alvarez-Ferreira J, Tapia B, et al. Acute generalized exanthematous pustulosis associated with pseudoephedrine. Br J Dermatol. 2004;150(1):139-142.
Assier-Bonnet H, Viguier M, Dubertret L, Revuz J, Roujeau JC. Severe adverse drug reactions due to pseudoephedrine from over-the-counter medications. Contact Dermatitis. 2002;47(3):165-182.
Kusutani N, Nishida M, Sowa-Osako J, Maekawa N, Fukai K. Acute generalized exanthematous pustulosis induced by pseudoephedrine in a combination tablet with fexofenadine. Int J Dermatol. 2021;60(7):e286-e288.
Blanes Martínez M, Silvestre Salvador JF, Vergara Aguilera G, Betlloch Mas I, Pascual Ramírez JC. Acute generalized exanthematous pustulosis induced by ranitidine hydrochloride. Contact Dermatitis. 2003;49(1):47.
Kuwabara Y, Sato A, Abe H, Abe S, Kawai N, Takeshita T. Ritodrine-induced pustular eruptions distinctly resembling impetigo herpetiformis. J Nippon Med Sch. 2011;78(5):329-333.
Kastalli S, Charfi O, El Aïdli S, Zaïem A, Daghfous R. Acute generalized exanthematic pustulosis induced by spiramycin: usefulness of patch testing. Tunis Med. 2016;94(7):339.
Zaouak A, Ben Salem F, Charfi O, Hammami H, Fenniche S. Acute generalized exanthematous pustulosis induced by terbinafine in a child confirmed by patch testing. Int J Dermatol. 2019;58(2):e42-e43.
Kempinaire A, De Raeve L, Merckx M, De Coninck A, Bauwens M, Roseeuw D. Terbinafine-induced generalized exanthematous pustulosis confirmed by a positive patch-test result. J Am Acad Dermatol. 1997;37(4):653-655.
Thomas E, Bellón T, Barranco P, et al. Acute generalized exanthematous pustulosis due to tetrazepam. J Investig Allergol Clin Immunol. 2008;18(2):119-122.
Cannavò SP, Borgia F, Guarneri F, Vaccaro M. Acute generalized exanthematous pustulosis following use of ticlopidine. Br J Dermatol. 2000;142(3):577-578.
Pettit C, Trinidad J, Kaffenberger B. A case of vancomycin-induced acute generalized exanthematous pustulosis confirmed by patch testing. J Clin Aesthet Dermatol. 2020;13(11):35-36.
Beeler A, Engler O, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol. 2006;117(2):455-462.
Özkaya E, Yazganoğlu KD, Kutlay A, Mahmudov A. Varenicline-induced acute generalized exanthematous pustulosis confirmed by patch testing. Contact Dermatitis. 2018;78(1):97-99.
Barbaud A, Bene MC, Faure G, Schmutz JL. Tests cutanés dans l'exploration des toxidermies supposées de mécanisme immuno-allergique. Bull Acad Natl Med. 2000;184(1):47-63. (Article in French, data cited in ref. 5).
Beylot C, Doutre MS, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg. 1996;15(4):244-249. (Data cited in ref. 5).
فهرسة مساهمة: Keywords: acute generalized exanthematous pustulosis; amoxicillin; beta-lactam antibiotics; delayed-type hypersensitivity; diltiazem; iodinated contrast media; positive patch tests; pristinamycin
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Pristinamycin)
804826J2HU (Amoxicillin)
تواريخ الأحداث: Date Created: 20220221 Date Completed: 20220718 Latest Revision: 20220720
رمز التحديث: 20221213
DOI: 10.1111/cod.14075
PMID: 35187690
قاعدة البيانات: MEDLINE
الوصف
تدمد:1600-0536
DOI:10.1111/cod.14075